EAN 2022 | Prognostic biomarkers in multiple sclerosis

Jens Kuhle, MD, PhD, University Hospital Basel, Basel, Switzerland, discusses the development of prognostic biomarkers in multiple sclerosis, highlighting serum neurofilament light (NfL) as a putative first-in-class biomarker. A plethora of global evidence supports the value of NfL as an objective measure of disease activity and treatment response, as well as having a prognostic role given its association with long-term clinical disease progression. Prof. Kuhle talks on efforts to establish reliable reference ranges for NfL which consider the impact of age, BMI, and renal function. This interview took place at the European Academy of Neurology (EAN) 2022 Congress in Vienna, Austria.